📊 INDV Key Takeaways
Is Indivior Pharmaceuticals, Inc. (INDV) a Good Investment?
Despite strong gross margins (87.4%) and modest revenue growth (4.3%), Indivior faces critical solvency issues: negative stockholders' equity of -$144M, negative operating cash flow of -$9M, and deteriorating liquidity ratios. The dramatic net income recovery (+2900% YoY) masks underlying cash generation weakness and suggests reliance on non-cash accounting adjustments rather than sustainable operational improvement. Liquidity stress indicators and high debt burden ($486M) create significant refinancing risk.
Indivior shows strong underlying profitability, with high gross margins, solid operating margins, and a sharp rebound in net income, indicating the core business remains economically attractive. However, that earnings strength is not currently translating into cash generation, and the combination of negative free cash flow, sub-1.0 liquidity ratios, and negative equity materially weakens the balance-sheet profile. The fundamentals support a neutral stance until cash conversion and financial health improve more clearly.
Why Buy Indivior Pharmaceuticals, Inc. Stock? INDV Key Strengths
- Exceptional gross margin of 87.4% indicates strong product pricing power
- Operating margin of 28.1% net margin demonstrates efficient cost structure
- Positive interest coverage ratio of 3.6x provides near-term debt servicing capacity
- Holding $175M in cash equivalents provides liquidity buffer
- High gross margin of 80.2% supports strong pricing power and favorable product economics
- Operating margin of 21.1% and net margin of 16.9% indicate solid earnings capacity
- Revenue growth of 4.3% with a major year-over-year improvement in net income suggests improving profitability
INDV Stock Risks: Indivior Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$144M indicates balance sheet is technically insolvent
- Negative operating cash flow (-$9M) and free cash flow (-$29M) despite GAAP profitability signals unsustainable business model
- Current ratio of 0.86x and quick ratio of 0.66x indicate acute liquidity stress and potential covenant violations
- Heavy debt load ($486M) combined with negative equity creates refinancing vulnerability
- Large YoY profit swing suggests prior period losses eroding shareholder value; recovery may not be sustainable
- Operating cash flow of negative $27.00M and free cash flow of negative $93.00M raise concerns about earnings quality and cash conversion
- Negative stockholders equity and total liabilities above total assets signal a weak balance-sheet cushion
- Current ratio of 0.71x and quick ratio of 0.55x indicate tight near-term liquidity
Key Metrics to Watch
- Operating cash flow trend - must return positive to validate profitability claims
- Stockholders' equity trajectory - critical to achieving positive equity position
- Current and quick ratios - must improve above 1.0x to indicate resolved liquidity stress
- Debt maturity schedule and refinancing capacity given negative equity constraints
- Operating cash flow and free cash flow trend
- Current ratio and stockholders equity recovery
Indivior Pharmaceuticals, Inc. (INDV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
INDV Profit Margin, ROE & Profitability Analysis
INDV vs Healthcare Sector: How Indivior Pharmaceuticals, Inc. Compares
How Indivior Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Indivior Pharmaceuticals, Inc. Stock Overvalued? INDV Valuation Analysis 2026
Based on fundamental analysis, Indivior Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Indivior Pharmaceuticals, Inc. Balance Sheet: INDV Debt, Cash & Liquidity
INDV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Indivior Pharmaceuticals, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-0.92 indicates the company is currently unprofitable.
INDV Revenue Growth, EPS Growth & YoY Performance
INDV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $266.0M | $47.0M | $0.38 |
| Q3 2025 | $307.0M | $7.0M | $0.05 |
| Q2 2025 | $299.0M | $7.0M | $0.05 |
| Q1 2025 | $266.0M | $7.0M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Indivior Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
INDV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Indivior Pharmaceuticals, Inc. (CIK: 0001625297)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INDV
What is the AI rating for INDV?
Indivior Pharmaceuticals, Inc. (INDV) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INDV's key strengths?
Claude: Exceptional gross margin of 87.4% indicates strong product pricing power. Operating margin of 28.1% net margin demonstrates efficient cost structure. ChatGPT: High gross margin of 80.2% supports strong pricing power and favorable product economics. Operating margin of 21.1% and net margin of 16.9% indicate solid earnings capacity.
What are the risks of investing in INDV?
Claude: Negative stockholders' equity of -$144M indicates balance sheet is technically insolvent. Negative operating cash flow (-$9M) and free cash flow (-$29M) despite GAAP profitability signals unsustainable business model. ChatGPT: Operating cash flow of negative $27.00M and free cash flow of negative $93.00M raise concerns about earnings quality and cash conversion. Negative stockholders equity and total liabilities above total assets signal a weak balance-sheet cushion.
What is INDV's revenue and growth?
Indivior Pharmaceuticals, Inc. reported revenue of $317.0M.
Does INDV pay dividends?
Indivior Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find INDV SEC filings?
Official SEC filings for Indivior Pharmaceuticals, Inc. (CIK: 0001625297) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INDV's EPS?
Indivior Pharmaceuticals, Inc. has a diluted EPS of $0.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INDV a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Indivior Pharmaceuticals, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INDV stock overvalued or undervalued?
Valuation metrics for INDV: ROE of N/A (sector avg: 15%), net margin of 28.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INDV stock in 2026?
Our dual AI analysis gives Indivior Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INDV's free cash flow?
Indivior Pharmaceuticals, Inc.'s operating cash flow is $-9.0M, with capital expenditures of $20.0M. FCF margin is -9.1%.
How does INDV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 28.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.86 (avg: 2).